Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$33.11 USD

33.11
1,040,983

+0.26 (0.79%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks News

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

InMode (INMD) to Post Q4 Earnings: What's in the Cards?

InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Will Tandem Diabetes Care Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Tandem Diabetes.

Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.

What's in the Offing for LabCorp's (LH) Earnings in Q4?

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?

Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

Nalak Das headshot

5 Top-Ranked Growth Stocks for February That Have Jumped YTD

Several positive factors have strengthened investors' confidence in risky assets like equities. A few top-ranked growth stocks surged in January and still have strong upside left.

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

Moving Average Crossover Alert: Tandem Diabetes Care

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Check 4 Best Liquid Bets to Power Your Portfolio

Four top-ranked liquid stocks that investors can bank on for fat returns.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Moving Average Crossover Alert: Tandem Diabetes Care

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.